Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular Inc demonstrated a robust financial performance with a gross margin expansion of 110 basis points year-over-year to 70%, driven by higher average selling prices and improved manufacturing efficiencies. The company reported a 15% increase in revenue, alongside a 12% rise in operating income to $16.1 million, resulting in a strong operating margin of 25%. Additionally, net income rose by 17% to $13.8 million, supporting a favorable outlook for continued sales growth and enhanced profitability with expectations of a gross margin of 69.7% for the year.

Bears say

LeMaitre Vascular Inc. anticipates a slight decline in its full-year operating margin, projected at 24%, reflecting typical seasonality effects and suggesting potential challenges in maintaining profitability. The company's reduced target for sales representatives, now set at 165, indicates a possible constraint on future growth and sales performance, diverging from previous projections. Furthermore, a significant decrease in R&D expenditure to 6% of revenue, attributed to the culmination of regulatory compliance projects, raises concerns about the firm's commitment to product innovation and its capacity to address competitive pressures and market demand effectively.

LeMaitre Vascular (LMAT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 6 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.